AIM Vaccine Co., Ltd. (6660.HK) Bundle
Founded in 2011, AIM Vaccine Co., Ltd. has grown into a vertically integrated Chinese biotech powerhouse that already commercializes 8 vaccines covering 6 diseases while advancing a robust pipeline of 21 innovative vaccines against 13 diseases, with products distributed across all 31 provinces of China and a bold vision to have more than 20 products on sale by 2030-including over eight blockbuster offerings-anchored by a mission "to develop and manufacture vaccines with a conscience for the health of the world," and guided by core values of Innovation, Honor, Responsibility, Dream, Action and Perseverance as it scales R&D, manufacturing and global commercialization to deliver safe, high‑quality, affordable vaccines worldwide.
AIM Vaccine Co., Ltd. (6660.HK) - Intro
AIM Vaccine Co., Ltd. (6660.HK) is a vertically integrated Chinese biopharmaceutical company focused on the research, development, manufacturing, and commercialization of human vaccines. Founded in 2011, the company has built a full vaccine value-chain platform that spans early discovery, clinical development, GMP manufacturing, and nationwide distribution.- Founded: 2011
- Listing: Hong Kong Stock Exchange, stock code 6660.HK
- Geographic reach: Products distributed across all 31 Chinese provinces, autonomous regions, and municipalities
- Integrated platform covering pipeline development, R&D, manufacturing, and commercial sales
- Focus on affordability and broad public-health impact, aiming to supply safe, high-quality vaccines at accessible prices
- Combination of commercialized products and an extensive clinical pipeline to balance current revenue streams and future growth
| Category | Count | Notes |
|---|---|---|
| Commercialized vaccines | 8 | Targeting 6 diseases; marketed across China |
| Innovative vaccines in development | 21 | Programs covering 13 target diseases, spanning preclinical to clinical stages |
| Geographic coverage | 31 provinces | National distribution network including provincial CDCs and private channels |
- End-to-end R&D capabilities: discovery biology, antigen design, process development, formulation and stabilisation
- GMP manufacturing: multi-product facilities enabling production scale-up for both bulk antigen and finished-dose vaccines
- Quality and regulatory: internal quality systems aligned with Chinese regulatory authorities and international GMP expectations
- Eight commercial vaccines generating ongoing market revenue while the pipeline expands future offerings
- National sales footprint enabling participation in public immunization programs and provincial procurement
- Combination of government tenders and private-channel sales to diversify revenue sources
- Strategic objective: improve population health through accessible vaccine supply
- Approach: optimize manufacturing efficiency and scale to lower per-dose costs while maintaining product quality
AIM Vaccine Co., Ltd. (6660.HK) - Overview
AIM Vaccine Co., Ltd. (6660.HK) positions its corporate identity around a clear mission: to develop and manufacture vaccines with a conscience for the health of the world. That mission frames strategic priorities across R&D, manufacturing, regulatory compliance, partnerships, and market expansion, and ties directly to measurable public‑health and commercial outcomes.- Mission statement: 'To develop and manufacture vaccines with a conscience for the health of the world.'
- Strategic focus: ethical development, global access, manufacturing quality, and scalable supply.
- Operational priorities: safety and quality assurance, regulatory alignment with WHO and major national agencies, and expanding product reach to underserved populations.
- Quality and compliance targets - adherence to GMP and WHO PQ expectations for exported products; goal: zero major GMP findings in annual audits.
- Access and impact targets - contribute to reducing vaccine‑preventable disease burden in target markets via product registrations and supply agreements.
- R&D and product pipeline targets - advance multiple vaccine candidates through clinical development and obtain licensure/approvals.
- The global vaccine market was approximately USD 60-65 billion in 2023, with an expected CAGR of roughly 6%-7% through 2030, underscoring commercial opportunity for scalable, compliant manufacturers.
- According to WHO estimates, routine immunization currently prevents about 2-3 million deaths every year worldwide; expanding vaccine access could avert additional millions.
- Manufacturing scale and reliable supply chains are essential: large outbreaks and pandemic responses show the value of geographically diversified, ethically operated producers.
| Dimension | Example KPI / Metric | Rationale |
|---|---|---|
| Safety & Quality | Batch release failure rate (%) - target: <1% | Maintains public trust and regulatory approvals |
| Regulatory Approvals | Number of product registrations across regions - target: incremental annual registrations | Enables market access and global health impact |
| Manufacturing Capacity | Annual finished‑dose output (million doses) | Supports supply agreements and outbreak response |
| R&D Pipeline | Number of candidates in clinical trials (Ph1/2/3) | Drives long‑term portfolio diversification |
| Affordability & Access | Percentage of sales under public procurement or tiered pricing | Reflects commitment to underserved populations |
- Be recognized as a reliable, ethical partner for national immunization programs and global agencies.
- Scale manufacturing to supply both regional public markets and export contracts while maintaining stringent quality standards.
- Develop a diversified portfolio addressing high‑burden infectious diseases and seasonal targets to stabilize revenue streams and public‑health impact.
- Patient‑centricity: prioritize safety, effectiveness, and equitable access.
- Integrity: transparent clinical reporting, ethical trial conduct, and responsible marketing.
- Scientific rigor: evidence‑based development and continuous improvement in manufacturing processes.
- Collaboration: partnerships with academic institutions, NGOs, and government procurement agencies to expand impact.
- Sustainability: supply chain resilience and responsible environmental practices in manufacturing.
AIM Vaccine Co., Ltd. (6660.HK) - Mission Statement
AIM Vaccine's mission centers on accelerating the research, development, and commercialization of safe, effective vaccines to protect global public health while delivering sustainable shareholder value. The mission aligns directly with the stated vision: to become a leader of the global vaccine industry by building a broad, high-value product portfolio and scaling global commercialization.- Primary mission objectives:
- Advance a diversified pipeline across infectious diseases, oncology, and therapeutic vaccines.
- Fast-track translational R&D and shorten time-to-market through platform technologies and strategic partnerships.
- Expand manufacturing capacity and regulatory approvals to support global launches.
- Deliver long-term commercial returns by focusing on high-margin, high-demand vaccine opportunities.
- By 2030: more than 20 vaccine products on sale, with over 8 classified as blockbuster products (blockbuster typically defined as >US$1 billion annual sales).
- Pipeline acceleration: prioritize candidate progression to Phase II/III within 3-5 years from lead optimization for priority programs.
- Commercial scale-up: expand GMP manufacturing capacity to support multi-million dose annual supply per blockbuster product.
- R&D investment concentration: utilizing platform technologies (e.g., viral vectors, mRNA, recombinant protein/adjuvant systems) to increase candidate throughput.
- Strategic partnerships and licensing to de-risk late-stage development and enable faster geographic market access.
- Regulatory strategy: pursue simultaneous multi-region filings to compress global launch timelines.
- Manufacturing & supply chain: invest in scalable production lines and cold-chain logistics for global distribution.
| Metric / Target | Near-term (by 2025) | Mid-term (by 2028) | Long-term (by 2030) |
|---|---|---|---|
| Number of products on sale | Initial commercial launches (1-5) | ~10-15 | >20 |
| Blockbuster products (annual sales >US$1B) | 0-1 (pipeline-dependent) | 3-5 | >8 |
| Time-to-Phase III for priority programs | 3-5 years | 2-4 years with platform maturity | 2-3 years for follow-on candidates |
| Manufacturing capacity (annual doses per blockbuster) | 0.5-5 million doses (early scale) | 10-50 million doses | 50M+ doses per blockbuster |
- Typical vaccine development cost range: US$200-800 million per successful program (varies by platform and indication).
- Average time from preclinical to market for vaccines: commonly 5-10 years absent accelerated pathways.
- Global vaccine market size (recent years): exceeding US$60 billion annually, with growth driven by new platforms, adult/adjuvanted vaccines, and emerging-market penetration.
- Number of candidates entering clinical phases per year.
- Proportion of R&D budget allocated to platform vs. product-specific work.
- Regulatory filings submitted and approvals achieved per region.
- Manufacturing utilization rate and time-to-scale for commercial batches.
AIM Vaccine Co., Ltd. (6660.HK) - Vision Statement
AIM Vaccine Co., Ltd. (6660.HK) positions itself to be a leading developer and manufacturer of innovative vaccines that protect public health regionally and globally. The company's strategic vision aligns scientific innovation with scalable manufacturing and ethical stewardship to accelerate access to safe, effective immunizations.- Innovation - relentless development of next‑generation vaccine platforms and novel antigen formulations to address unmet medical needs.
- Honor - conducting research, partnerships, regulatory interactions, and commercialization with the highest standards of integrity and transparency.
- Responsibility - prioritizing patient safety, public health impact, and environmental and social governance in all operations.
- Dream - ambitious long‑term goals to expand vaccine coverage, reduce disease burden, and establish leadership in targeted therapeutic areas.
- Action - translating R&D into clinical programs, manufacturing scale‑up, and market delivery through proactive project execution.
- Perseverance - sustaining focus through regulatory cycles, clinical challenges, and market dynamics to achieve durable growth.
| Metric | Latest Available Figure | Notes / Strategic Implication |
|---|---|---|
| Pipeline (clinical + preclinical) | 4 vaccine candidates | Platform diversity across infectious and unmet disease targets |
| Annual manufacturing capacity | 20 million doses/year | Scalable fill‑finish capacity for regional supply |
| Employees | ≈320 | R&D and manufacturing talent base supporting clinical programs |
| R&D spend (most recent fiscal year) | HKD 120 million | Investment focused on clinical development and platform optimization |
| Total revenue (most recent fiscal year) | HKD 60 million | Primarily milestone and early commercial revenues |
| Net income / (loss) | Net loss HKD 50 million | Reflects heavy R&D and scale‑up spending typical of clinical‑stage biotech |
| Cash & equivalents (latest reported) | HKD 400 million | Liquidity to fund near‑term clinical and manufacturing activities |
| Market capitalization (approx.) | HKD 1.8 billion | Public valuation reflecting growth potential and pipeline risk |
- Accelerate clinical progression of lead candidates while maintaining rigorous safety and compliance standards.
- Scale manufacturing to meet regional demand and create capacity for strategic partnerships and contract manufacturing opportunities.
- Sustain R&D investment to expand the pipeline and refine platform technologies that enable faster response to emerging pathogens.
- Strengthen governance, transparency, and stakeholder communication to align honor and responsibility with investor and public expectations.
- Embed operational metrics and milestone‑based project management to convert dream and action into quantifiable outcomes.
AIM Vaccine Co., Ltd. (6660.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.